The effect of cannabinoids on prostate specific antigen (PSA) and positron emission tomography/ computerized tomography (PET) scan results of patients diagnosed with prostate cancer who are using medical cannabis

Cannabis Research Council0 个研究点目标入组 90 人开始时间: 2023年10月30日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•Patients who have been diagnosed with prostate cancer as the primary cancer.
•Patients who have had radiation and /or chemotherapy and are self-medicating on medical cannabis oil for more than a period of 3 months; or
•Patients who have not had any radiation and/ or chemotherapy and are still self-medicating on medical cannabis oil more than a period of 3 months; or
•Patients receiving radiation and/ chemotherapy only, and not taking any medical cannabis oil more than a period of 3 months.
•Patients making their own cannabis oil will be included in the study, provided the THC and CBD in the cannabinoid profile is between 10 mg to 20 mg for both CBD and THC.
•Participants taking proprietary cannabis oils approved for medicinal use in hand in terms of a Section 21 exclusion, provided the CBD and THC range between 10 mg to 20 mg.

•Patients younger than 21 years of age.
•Patients who are deemed palliative in nature (expectation of passing in less than six months).
•Patients who are diagnosed with Schizophrenia or any other psychotic disorders.
•Stage one prostate cancer.
•Patients who had a Prostatectomy.
•Patients smoking cannabis.
•Participants of the pilot study.
•Participants who will not give written informed consent.
•Participants who will not provide the cannabis oil they use for testing.
•Patients using cannabis recreationally.

发起方

Cannabis Research Council